Sigurdsson J A, Ahlmén J, Berglund L, Jerneck M, Larsson L, Lincoln K, Wohrm A, Bucht H
Acta Med Scand. 1983;213(1):55-60. doi: 10.1111/j.0954-6820.1983.tb03690.x.
The aim of this study was to determine if a three-day treatment of lower urinary tract infection (UTI) is effective. 215 women with symptoms of lower UTI, seen in general practice, were randomly allocated to a double-blind study and given either amoxycillin 1000 mg twice a day for three days or trimethoprim 90 mg/sulphadiazine 410 mg (co-trimazine) 2 tablets initially, then one tablet twice daily for three days. 157 women (73%) had significant bacteriuria. Therapeutic efficacy was evaluated in 146 patients. One week after treatment had started, 88% of the women in the amoxycillin group and 100% in the co-trimazine group were cured (p less than 0.01). After a follow-up period of four weeks, the cumulative relapse frequencies were 19% and 9% respectively. Adverse reactions were mild in most cases. Two patients, both on co-trimazine, had to discontinue treatment because of nausea and vomiting. Vulvovaginal irritation was more often reported by women treated with amoxycillin (n = 8) than by those treated with co-trimazine (n = 1) (p less than 0.05). It is concluded that a three-day course of amoxycillin or co-trimazine in lower UTI is safe, causes few adverse reactions, is simple to administer and comfortable for the patient. Co-trimazine seems to be more effective than amoxycillin.
本研究的目的是确定为期三天的下尿路感染（UTI）治疗是否有效。215名在全科医疗中出现下尿路感染症状的女性被随机分配到一项双盲研究中，她们被给予阿莫西林1000毫克，每日两次，共三天，或者给予甲氧苄啶90毫克/磺胺嘧啶410毫克（复方新诺明），最初服用2片，然后每日两次，每次1片，共三天。157名女性（73%）有显著菌尿。对146名患者评估了治疗效果。治疗开始一周后，阿莫西林组88%的女性和复方新诺明组100%的女性被治愈（p小于0.01）。在四周的随访期后，累积复发率分别为19%和9%。大多数情况下不良反应较轻。两名服用复方新诺明的患者因恶心和呕吐不得不停止治疗。服用阿莫西林治疗的女性（n = 8）比服用复方新诺明治疗的女性（n = 1）更常报告有外阴阴道刺激症状（p小于0.05）。结论是，阿莫西林或复方新诺明治疗下尿路感染三天疗程是安全的，不良反应少，给药简单，患者感觉舒适。复方新诺明似乎比阿莫西林更有效。
